Post Operative Treatment
SIMPLIFIED

About SmartDrops™ Technology

SmartDrops™ is a patent pending pharmaceutical solution matrix technology created specifically for stabilizing multiple active pharmaceutical ingredients (API) that do not typically mix. The technology micronizes the particles to enhance solubility, create uniform distribution, balance the pH, and maintain the specific of gravity in order to obtain one complete isotonic solution having the ideal osmolarity. Smart Drops technology was designed to combine multiple ophthalmic medications into one easy to use formula.

SmartDrops™ is designed to require 50% fewer drops to be administered by patients and may provide a significant cost savings of up to 75% compared to current traditional post-surgery eye drop treatments.

The average retail price for three commonly prescribed post cataract drops is $482. This is based on Vigamox at $128.79 Durezol at $194.84 and Ilevro at $159.28. Many times these branded drugs and their generic alternatives are not covered by drug plans and when the drugs are covered, the copays for the three separate drugs typically exceed $75. When the drugs are not covered, they cause huge financial burdens for the patients and unnecessary aggravation for the physician. Ultimately, the non-covered drugs become the problem of the physician, causing the physician to find alternatives, provide samples or absorb the cost of the medications on behalf of the patient.

Benefits

Benefits / Advantages of Using SmartDrops™

  • Less Drops (up to 50% fewer drops used)
  • Eliminates Confusion (amongst different drops)
  • Fewer Bottles (1 vs 3)
  • Improved Compliance (easy and simple administration)
  • Costs Less (Cash price is usually less than commercial drug co-pays for three products)
  • Guaranteed Fulfillment (without unknown of insurance reimbursable)
  • Less Pharmacy Call Backs (improved efficiency for physician’s office)
  • Healthcare Savings (cost to patient remains same or less and reduces burden to Medicare)

Ophthalmology Market Opportunity

Cataract surgery is one of the most common surgical procedures in the world. A recent Market Scope report states that 22 million procedures were performed globally in 2013 with 3.6 million of of those procedures occurring in the US. Over half of Americans require some form of vision correction and approximately 43 million of them are candidates for refractive surgery. Nearly 96% of refractive procedures performed today are LASIK (laser in situ keratomileusis), an outpatient surgical procedure used to treat nearsightedness, farsightedness, and astigmatism. Over 35 million LASIK procedures have been performed worldwide since receiving FDA approval in 1999, with an estimated 700,000 annually in the United States.

In order to treat post-intraocular surgery infection and inflammation, patients have to administer multiple eye drops. Eye drops require strict compliance and careful adherence to a prescribed dosing regimen. Physicians have reported and recent studies have shown that eye drop regimens can be confusing to patients, leading to non-compliance and incorrect dosing. Eye drops are an expensive component to post-operative care for all patients, even ones with the best insurance plans. And the price continues to soar.

Cataract eye drops have become more expensive in the past year. The massive price of drops is mainly attributed to the hundreds of different health insurance drug benefit plans. The drug companies have to make arrangements with each one of these plans to try and make the cost of their cataract eye drops affordable. Each year these arrangements change, so one year the cataract eye drops could be reasonable with certain plans while the next they could be completely unaffordable. In some cases, the companies that own the branded cataract eye drops have also purchased the companies that make the generic cataract eye drops. Recently, the trend has been that pharmaceutical companies have raised the price of the generics to a similar price as the branded products. Many of the branded products have co-pay assistance coupons to make the drug affordable, however, most times they are not accepted by pharmacies due to the recipients having Medicare part D. Not being able to use the co-pay assistance often makes the drug expensive and a burden for many patients.

Up until now patients had no other alternative regarding post operative drops. Now patients have the option of obtaining drops at the lowest price, regardless of insurance reimbursement and pharmaceutical drug pricing strategies.

Products

We have developed three products using the SmartDrops™ Technology, which incorporate the most commonly prescribed medications post surgery; Antibiotic, NSAID and Steroid into one easy to use drop.

Smartdrops Products

We have developed three core formulations:
Steroid + Anti-Infective
Steroid + NSAID
Steroid + Anti-Infective + NSAID

Procedure Formulation Mechanism
LASIK 1% Prednisolone / 0.5% Moxifloxacin Steroid / Anti-Infective
Cataract 1% Prednisolone / 0.4% Ketorolac Steroid / NSAID
Cataract 1% Prednisolone / 0.5% Moxifloxacin / 0.4% Ketorolac Steroid / Anti-Infective / NSAID

Anti-Infective Medication

Antibiotic treatments are routinely administered after cataract surgery for the first few weeks. They are intended to help decrease the chance of infection inside the eye.

Non-Steroidal Anti-inflammatory (NSAID) Medication

Nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.

Steroid Medication

Glucocorticoids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as well as capillary proliferation, deposition of collagen, and scar formation.

SmartDrops™ Availability

Contact Us

To learn more about SmartDrops, request additional information, please complete and submit this form.